A partner and co-chair of the Litigation Department, Theodore V. Wells, Jr. has extensive litigation experience in white-collar defense, complex civil and corporate litigation, SEC regulatory work, healthcare fraud, FCPA, AML and OFAC investigations, environmental matters and class action litigation.
In 2010, Ted successfully defended Citigroup in a three-week jury trial where the plaintiff, the London-based private equity firm Terra Firma, claimed it was defrauded in connection with its purchase of the music company EMI, and claimed over $8 billion in damages.
In 2008, Ted successfully defended Citigroup in a five-month jury trial where the plaintiff alleged that Citigroup aided and abetted in the massive fraud at Parmalat, the Italian dairy and food corporation. The jury totally rejected the $2 billion claim for damages against Citigroup and also awarded Citigroup $364 million on Citigroup's counterclaim.
In 2012, Ted served as lead trial counsel for Bank of America in the massive securities class action relating to Bank of America's acquisition of Merrill Lynch & Co. The case was settled on the eve of trial.
In 2013, Ted served as lead counsel for Merck in the massive securities fraud class action relating to the drug Vytorin. The case was settled on the eve of trial.
Ted was lead trial counsel for Merck in the federal regulatory investigations related to Vioxx and was lead counsel for Abbott Laboratories in the federal regulatory investigations relating to Depakote. Both the Vioxx and Depakote federal regulatory investigations were successfully settled in 2012.